Zdrowie i gospodarka · 30/07/2026

FDA Announces Generic Drug User Fee Rates for Fiscal Year 2027

The US Food and Drug Administration (FDA) has published the fiscal year 2027 rates for fees related to the review of generic drugs, as mandated by the Generic Drug User Fee Amendments of 2022 (GDUFA III). These fees will be used to support the agency's efforts to review and approve generic drug applications.